Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules

NCT ID: NCT03651986

Last Updated: 2023-05-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

10560 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-26

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

AnchorDx is using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS) to develop a blood-based assay for differentiating benign and malignant pulmonary nodules early. The purpose of this study is to evaluate the diagnostic performance of this assay in patients with pulmonary nodules.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multi-center, observational cohort study and seeks to enroll 10,560 participants with pulmonary nodules smaller than 3 cm in diameter from 21 hospitals in China. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years ( baseline, 3 months, 6 months, 12 months, 24 months and 36 months). Their blood samples, CT or LDCT scans data, and clinical data will be collected at each visit and Formalin-fixed paraffin-embedded (FFPE) tissues will be collected when participants who receive pneumonectomy or percutaneous lung biopsy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Nodules

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prospective Cohort

This is a prospectively enrolling cohort study and a stratified case-cohort design will be employed to select malignant pulmonary nodules cases and benign pulmonary nodules subjects who will be assayed. All participants will be followed up with chest CT or low-dose computed tomography (LDCT) scans for 2-3 years, and take the diagnostic test, ctDNA methylation analysis by NGS, at each visit.

ctDNA methylation analysis by NGS

Intervention Type DIAGNOSTIC_TEST

A blood-based assay for differentiating benign and malignant pulmonary nodules early using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ctDNA methylation analysis by NGS

A blood-based assay for differentiating benign and malignant pulmonary nodules early using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 Years and older
* pulmonary nodules diagnosed by chest CT or low-dose computed tomography (LDCT) scans

* non-calcified pulmonary nodules with the diameter between 5mm to 30mm
* including solid nodules, mixed ground-glass opacity nodules and pure ground-glass opacity lung modules
* new cases of pulmonary nodules or diagnosed within 60 days prior to enrollment
* agree to finish the Patient Pulmonary History Questionnaire
* agree to be followed up for 2-3 years
* agree to provide a written informed consent

Exclusion Criteria

* pregnant or lactating women
* received any pneumonectomy or percutaneous lung biopsy before enrollment
* recipients of blood transfusions within 30 days prior to enrollment
* patients with tumors identified within 2 years prior to enrollment except non-melanoma skin cancer
* fail to understand or provide a written informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xiangya Hospital of Central South University

OTHER

Sponsor Role collaborator

West China Hospital

OTHER

Sponsor Role collaborator

Shanghai Zhongshan Hospital

OTHER

Sponsor Role collaborator

Shanghai Pulmonary Hospital affiliated to Tongji University

UNKNOWN

Sponsor Role collaborator

First Hospital of China Medical University

OTHER

Sponsor Role collaborator

Guizhou Provincial People's Hospital

OTHER

Sponsor Role collaborator

Shanghai Chest Hospital

OTHER

Sponsor Role collaborator

First Affiliated Hospital, Sun Yat-Sen University

OTHER

Sponsor Role collaborator

First Affiliated Hospital Xi'an Jiaotong University

OTHER

Sponsor Role collaborator

Qilu Hospital of Shandong University

OTHER

Sponsor Role collaborator

Inner Mongolia People's Hospital

OTHER

Sponsor Role collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

Sponsor Role collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

Sponsor Role collaborator

Second Hospital of Jilin University

OTHER

Sponsor Role collaborator

LanZhou University

OTHER

Sponsor Role collaborator

Peking University Third Hospital

OTHER

Sponsor Role collaborator

The First People's Hospital of Yunnan

OTHER

Sponsor Role collaborator

Shantou Affiliated Hospital of Sun Yat-Sen University

UNKNOWN

Sponsor Role collaborator

Ruijin Hospital

OTHER

Sponsor Role collaborator

Tongji Hospital

OTHER

Sponsor Role collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

Sponsor Role collaborator

The First Affiliated Hospital of Air Force Medicial University

OTHER

Sponsor Role collaborator

Shenzhen People's Hospital

OTHER

Sponsor Role collaborator

Henan Provincial People's Hospital

OTHER

Sponsor Role collaborator

Beijing Chao Yang Hospital

OTHER

Sponsor Role collaborator

Xiamen Second Hospital

UNKNOWN

Sponsor Role collaborator

The First Affiliated Hospital of Nanchang University

OTHER

Sponsor Role collaborator

AnchorDx Medical Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nanshan ZHONG, MD

Role: STUDY_CHAIR

The First Affiliated Hospital of Guangzhou Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital

Beijing, , China

Site Status

Xiangya Hospital of Central South University

Changsha, , China

Site Status

Department of Respiratory Medicine, West China Hospital of Sichuan University

Chengdu, , China

Site Status

Department of Pulmonary Medicine, The First Affiliated Hospital of Sun Yat-Sen University

Guangzhou, , China

Site Status

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, , China

Site Status

Department of Respiration and Critical Care Medicine, Guizhou Provincial People's Hospital

Guiyang, , China

Site Status

Department of Pulmonary and Critical Care Medicine, Inner Mongolia Autonomous Region People's Hospital

Hohhot, , China

Site Status

Department of Respiratory, QILU Hospital, Shandong University

Jinan, , China

Site Status

Department of Respiratory Medicine, The First People's Hospital of Yunnan Province

Kunming, , China

Site Status

Department of Gerontal Respiratory Medicine, The Frist Hospital of Lanzhou University

Lanzhou, , China

Site Status

Department of Respiration, The First Affiliated Hospital of Nanchang University

Nanchang, , China

Site Status

Department of Pulmonary & Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, , China

Site Status

Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University

Shanghai, , China

Site Status

Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University

Shanghai, , China

Site Status

Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Shanghai, , China

Site Status

Department of Respiratory Medicine, Shantou Central Hospital

Shantou, , China

Site Status

Department of Respiratory Medicine, The First Hospital of China Medical University

Shenyang, , China

Site Status

Department of Respiratory Medicine, Shenzhen People's Hospital

Shenzhen, , China

Site Status

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Wuhan, , China

Site Status

Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital, Xi'an Jiaotong University

Xi'an, , China

Site Status

Department of Pulmonary Medicine, Xijing Hospital, Air Force Medical University of PLA

Xi'an, , China

Site Status

Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Xiamen Medical College

Xiamen, , China

Site Status

Department of Respiratory Medicine, Henan Provincial People's Hospital

Zhengzhou, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Liang W, Liu D, Li M, Wang W, Qin Z, Zhang J, Zhang Y, Hu Y, Bao H, Xiang Y, Wang B, Wu J, Sun J, Hu C, Ye X, Zhang X, Xiao W, Yun C, Sun D, Wang W, Chang N, Zhang Y, Zhao J, Zhang X, Xu J, Wu D, Liu X, Guo Y, Zhang Q, Zhang W, Yang L, Li Z, Zhang X, Han B, Tong Z, He J, Qu J, Fan JB, Zhong N. Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases. Transl Lung Cancer Res. 2020 Oct;9(5):2016-2026. doi: 10.21037/tlcr-20-701.

Reference Type DERIVED
PMID: 33209621 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AnchorDx LC201801

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.